Abstract

BackgroundEarly cancer recurrence after oesophagectomy is a common problem, with an incidence of 20–30 per cent despite the widespread use of neoadjuvant treatment. Quantification of this risk is difficult and existing models perform poorly. This study aimed to develop a predictive model for early recurrence after surgery for oesophageal adenocarcinoma using a large multinational cohort and machine learning approaches.MethodsConsecutive patients who underwent oesophagectomy for adenocarcinoma and had neoadjuvant treatment in one Dutch and six UK oesophagogastric units were analysed. Using clinical characteristics and postoperative histopathology, models were generated using elastic net regression (ELR) and the machine learning methods random forest (RF) and extreme gradient boosting (XGB). Finally, a combined (ensemble) model of these was generated. The relative importance of factors to outcome was calculated as a percentage contribution to the model.ResultsA total of 812 patients were included. The recurrence rate at less than 1 year was 29·1 per cent. All of the models demonstrated good discrimination. Internally validated areas under the receiver operating characteristic (ROC) curve (AUCs) were similar, with the ensemble model performing best (AUC 0·791 for ELR, 0·801 for RF, 0·804 for XGB, 0·805 for ensemble). Performance was similar when internal–external validation was used (validation across sites, AUC 0·804 for ensemble). In the final model, the most important variables were number of positive lymph nodes (25·7 per cent) and lymphovascular invasion (16·9 per cent).ConclusionThe model derived using machine learning approaches and an international data set provided excellent performance in quantifying the risk of early recurrence after surgery, and will be useful in prognostication for clinicians and patients.

Highlights

  • To include neoadjuvant chemoradiotherapy (NACRT) as a factor in the model, further patients were identified from University Hospitals Southampton and University Medical Centre (UMC) Utrecht, where CROSS (Chemoradiation for Oesophageal Cancer Followed by Surgery Study)-type NACRT4 has been the standard of care for oesophageal adenocarcinoma for a number of years

  • Patients in the early recurrence group were significantly less likely to have responded to neoadjuvant treatment (8⋅5 versus 21⋅7 per cent), had worse ypT and ypN categories, R1 resection rate and grade of differentiation, and were more likely to have lymphovascular invasion (Table 1)

  • An easy-to-use and robust clinical model for predicting the risk of early recurrence after surgery for oesophageal adenocarcinoma was derived in this study

Read more

Summary

Introduction

Recurrence (less than 1 year) after surgery is a feared outcome, with rates of 20–30 per cent frequently reported[3,4,5], despite the increasing uptake of neoadjuvant chemotherapy (NACT) and neoadjuvant chemoradiotherapy (NACRT). Cancer recurrence after oesophagectomy is a common problem, with an incidence of 20–30 per cent despite the widespread use of neoadjuvant treatment. Quantification of this risk is difficult and existing models perform poorly. Conclusion: The model derived using machine learning approaches and an international data set provided excellent performance in quantifying the risk of early recurrence after surgery, and will be useful in prognostication for clinicians and patients

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call